跳至主要内容
临床试验/CTRI/2022/03/040923
CTRI/2022/03/040923尚未招募未知

Standard medical therapy plus rifaximin vs. standard medical therapy alone for the management of sarcopenia in patients with cirrhosis: A PILOT Randomized Controlled Trial

AIIMS New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Patients with cirrhosis (Child A and B) and sarcopenia
  • 2.Age: 18-60 years

排除标准

  • 1.Patients with history of overt hepatic encephalopathy (HE) or those who develop HE during treatment
  • 2.Patients with sepsis, active GI bleed or acute kidney injury
  • 3.Known cases of hepatocellular carcinoma
  • 4.Any severe chronic illness including congestive heart failure, chronic kidney disease, neuromuscular disorders or HIV
  • 5.History of any chronic drug intake such as corticosteroids
  • 6.History of drugs postulated to increase muscle mass such as testosterone, growth hormone, anabolic steroids

研究者

发起方
AIIMS New Delhi

相似试验